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Oncolytic viruses, by deﬁnition, are viruses that are capable
of infecting and selectively replicating in cancer cells, even-
tually leading to cell death without harming healthy cells.
The concept of using viruses to treat cancer dates back over a
century. There was renewed interest in oncolytic virotherapy
in the 1990s after the ﬁrst genetically engineered oncolytic
virus,aherpessimplexvirus-1thymidinekinasemutant,was
reportedin1991.Overthelasttwodecadesgreatprogresshas
been made in this ﬁeld, and several oncolytic viruses have
entered into clinical trials. This special issue on oncolytic
viruses addresses some of the challenges that need to be
overcome in order to achieve success in the clinic.
Oncolytic viruses can be delivered into cancer patients
or preclinical animal models by a number of routes includ-
ing intratumoral, intravenous, intrapleural, intraperitoneal
delivery and hepatic artery infusion. Although intratumoral
injectionhasbeenwidelystudiedbothpreclinicallyandclini-
cally, systemic delivery is the preferred method for treatment
of the patient populations in greatest need of new eﬃcacious
therapies those with metastatic or inaccessible disease. The
paper by M. S. Ferguson et al. summarizes the data from
clinical trials using systemically delivered oncolytic viruses
and then identiﬁes barriers to this delivery approach and
proposes solutions.
The host immune response is a double-edged sword to
the success of oncolytic virotherapy. The paper by C. A.
Alvarez-Breckenridge et al. discusses the multifaceted rela-
tionship between oncolytic viruses and natural killer (NK)
cells,a key component of innate immunity. The NK response
to oncolytic virotherapy results in premature viral clearance
while also mediating downstream antitumor immunity.
Thus, it is critical to ﬁnd an optimal approach to ﬁnely
balance host antiviral and antitumoral immune responses.
T h ep a p e rb yM .H .V e r h e i j ea n dP .J .M .R o t t i e rr e v i e w s
the transduction targeting strategies currently employed to
generate new oncolytic viruses with improved tumor speci-
ﬁcity. The authors discuss advantages and limitations of each
strategy by examples, and special attention is given to viruses
expressing a bispeciﬁc adaptor protein consisting of two
domains, one binding to the virion, the other to a cell surface
protein of interest.
Hematopoieticstemcelltransplant(HCT)isusedtotreat
hematological malignancies; however, the contamination of
healthy hematopoietic stem and progenitor cells with cancer
cells presents a major challenge. The paper by S. Bais et al.
provides a detailed review of using oncolytic viruses to treat
hematological malignancies, and in particular, the use of
oncolytic viruses to purge contaminating cancer cells for
HCT.
Manynewoncolyticviruseshavebeengeneratedthrough
genetic engineering based on rational design. The paper by
M.BauzonandT.Hermistonpresentsanalternativemethod,
that is, directed evolution that involves passaging diverse
viruses under conditions that mimic the human cancer
microenvironment. Using ColoAd1, the ﬁrst directed evol-
ution-derived oncolytic virus as an example, the authors2 Advances in Virology
underline the beneﬁts of directed evolution and propose
methods to “arm” these novel viruses and control their repli-
cation.
This special issue highlights some important recent
ﬁndings in the ﬁeld of oncolytic virotherapy and addresses
challenges that the ﬁeld is currently facing. Several oncolytic
viruses have already entered, or will be entering randomized
phase III trials. Amgen, the largest independent biotechno-
logy company, has recently joined the ﬁeld through acqui-
sition of Biovex, highlighting the promising future of this
therapeutic approach.
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